Correlation between MEK signature and Ras gene alteration in advanced gastric cancer.

MEK inhibitor (selumetinib) is a potent, orally active inhibitor of MAPK/ERK pathway. It is important to develop an accurate and robust method indicative of RAS pathway activity to stratify potential patients who can benefit from selumetinib treatment in gastric cancer (GC). First, we surveyed the sensitivity to selumetinib in a panel of 22 GC cell lines and correlated with MEK signature to selumetinib sensitivity. Next, we analyzed MEK signature via nanostring assay in two Asian cohorts using clinical samples ( = 218) and then performed a correlative analysis with MEK signature status and genotype in GC. MEK signature was predictive of response of selumetinib in GC cell lines regardless of mutation status. The proportion of high MEK signature by nanostring assay was 6.9% and the proportion of high MEK signature was significantly higher in altered group in a Korean cohort. None of altered cases belonged to high MEK signature group. MEK high signature was more prevalent in intestinal type by Lauren classification. The correlation between MEK signature, alteration and treatment response to selumetinib should be validated in prospective clinical trials.